Skip to main content
Premium Trial:

Request an Annual Quote

EU Liquid Biopsy Consortium to Evaluate Angle's CTC Isolation Tech

NEW YORK (GenomeWeb) – Angle PLC said today that it has been formally selected to work with Europe's Cancer-ID consortium, which seeks to establish standard protocols for the clinical validation of blood-based biomarkers to bring liquid biopsy testing into routine clinical practice.

Funded by the EU's Innovative Medicines Initiative, Cancer-ID has a total budget of more than €14 million ($14.84 million).

The effort includes partners from 13 countries and is coordinated by University Medical Center Hamburg-Eppendorf, University of Twente, Bayer AG, and Menarini Silicon Biosystems.

Angle said it will contribute several Parsortix instruments and associated consumables to the consortium for evaluation.

Cancer-ID researchers will first judge the suitability of Parsortix to serve as a standard method for circulating tumor cell harvesting, to be used alongside various molecular analysis techniques. 

After this initial evaluation phase, the consortium will move to a validation phase designed to provide clinical evidence to support the adoption of liquid biopsy in routine cancer care.